March 26, 2020

Gratitude

All of us are more than a little panicked about COVID-19. This is such an uncertain time and these frightening feelings can be contagious as well. But so are feelings of kindness, positivity, gratitude, and…

Learn More

March 25, 2020

NS Pharma Announces Marketing Authorization in Japan of VILTEPSO® for the Treatment of Duchenne

Good news out of Japan! NS Pharma, Inc., announced that their parent company, Nippon Shinyaku Co., Ltd., has received approval for viltolarsen in Japan for people with Duchenne amenable to exon 53 skipping therapy. Viltolarsen…

Learn More

March 23, 2020

WATCH: Family Friday – Home Schedules & School

Webinar Recording: Family Friday – Home Schedules & School For many of us, self-quarantine is in full swing, and adjusting to a different family structure may be overwhelming. So your PPMD family is launching Family…

Learn More

March 23, 2020

NS Pharma Shares Community Letter Regarding COVID-19

NS Pharma, Inc. has shared an update with the community responding to questions about how COVID-19 may be affecting ongoing studies of viltolarsen, the recently launched Expanded Access Program (EAP) and review of the viltolarsen…

Learn More

March 23, 2020

ReveraGen BioPharma Shares Community Update on Vamorolone Trials and COVID-19

ReveraGen has shared an update with the community regarding the Vamorolone trials and COVID-19. Read the Community Letter from ReveraGen Dear Duchenne families, As we are all confronted with the uncertainty of Covid-19, the team…

Learn More

March 19, 2020

WATCH: COVID-19 & Duchenne – What you need to know

Webinar Recording: COVID-19 & Duchenne – What you need to know Earlier today, PPMD hosted a webinar with experts from our Certified Duchenne Care Centers (CDCCs) to educate our community on the current state of COVID-19, as…

Learn More

March 19, 2020

Sarepta Therapeutics Shares Community Update on COVID-19

Sarepta Therapeutics has provided the community with an update addressing questions from the community regarding COVID-19, including updates on current clinical trials and accessing approved therapies. Read Sarepta’s Update March 19, 2020 Dear Duchenne and…

Learn More

March 18, 2020

Catabasis Shares Update on Edasalonexent and COVID-19

Catabasis Pharmaceuticals has shared an update responding to questions about edasalonexent and COVID-19. To date, Catabasis has not identified any safety concerns related to COVID-19, and they continue to monitor the trial for the safety…

Learn More

March 17, 2020

COVID-19 & Duchenne: FAQs

March 23, 2020 Update: Please click here to view our most recent COVID-19 information & FAQs. COVID-19 & Duchenne: FAQs We recognize that as the COVID-19 (coronavirus) pandemic continues to evolve and new cases are…

Learn More

March 16, 2020

PTC Shares Update on EMFLAZA Availability During Coronavirus

PTC Therapeutics has shared a statement on EMFLAZA availability during the coronavirus (COVID-19) crisis, stating that the supply of EMFLAZA will not be affected by the coronavirus (COVID-19). PTC reports that they are closely monitoring…

Learn More